🎉 Pharmidex at the 7th Forum on Respiratory Tract Infections! 🫁🔬
January 30, 2025
We are proud to announce that Ian Knowles, Head of Respiratory at Pharmidex, will be attending the 7th Forum on Respiratory Tract Infections in Glasgow from February 3rd to 5th, 2025!
This prestigious event brings together experts from across the industry to discuss the latest advancements in respiratory research, and Ian is looking forward to connecting with fellow professionals, sharing insights, and fostering positive collaborations.
If you’re attending, don’t miss the chance to meet Ian and explore opportunities to work together!
💬 Want to schedule a chat? Reach out to us!
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. ✅ Human-relevant metabolism data ✅ Supports IND-enabling ®gulatory studies ✅ Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. 📩 Contact us to see how 8HUM can support your project.
